• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嵌合抗原受体(CAR)介导的张力信号分析。

Analysis of CAR-Mediated Tonic Signaling.

作者信息

Calderon Hugo, Mamonkin Maksim, Guedan Sonia

机构信息

Department of Hematology and Oncology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.

出版信息

Methods Mol Biol. 2020;2086:223-236. doi: 10.1007/978-1-0716-0146-4_17.

DOI:10.1007/978-1-0716-0146-4_17
PMID:31707680
Abstract

CARs are synthetic receptors designed to drive antigen-specific activation upon binding of the scFv to its cognate antigen. However, CARs can also elicit different levels of ligand-independent constitutive signaling, also known as tonic signaling. Chronic T cell activation is observed in certain combinations of scFv, hinge, and costimulatory domains and may be increased due to high levels of CAR expression. Tonic signaling can be identified during primary T cell expansion due to differences in the phenotype and growth of CAR-T cells compared to control T cells. CARs displaying tonic signaling are associated with accelerated T cell differentiation and exhaustion and impaired antitumor effects. Selecting CARs which configuration does not induce tonic signaling is important to enhance antigen-specific T cell responses. In this chapter, we describe in detail different protocols to identify tonic signaling driven by CARs during primary T cell ex vivo expansion.

摘要

嵌合抗原受体(CAR)是一种合成受体,设计用于在单链抗体片段(scFv)与其同源抗原结合时驱动抗原特异性激活。然而,CAR也可引发不同水平的不依赖配体的组成性信号传导,也称为张力信号传导。在scFv、铰链区和共刺激结构域的某些组合中观察到慢性T细胞激活,并且由于CAR的高表达水平,这种激活可能会增加。由于与对照T细胞相比,CAR-T细胞在表型和生长方面存在差异,因此在原发性T细胞扩增过程中可以识别张力信号传导。显示张力信号传导的CAR与T细胞分化加速、耗竭以及抗肿瘤作用受损有关。选择不诱导张力信号传导的CAR构型对于增强抗原特异性T细胞反应很重要。在本章中,我们详细描述了在原发性T细胞体外扩增过程中识别由CAR驱动的张力信号传导的不同方案。

相似文献

1
Analysis of CAR-Mediated Tonic Signaling.嵌合抗原受体(CAR)介导的张力信号分析。
Methods Mol Biol. 2020;2086:223-236. doi: 10.1007/978-1-0716-0146-4_17.
2
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.联合CD28和4-1BB共刺激增强亲和力优化的嵌合抗原受体工程化T细胞。
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.
3
Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.嵌合抗原受体T细胞(CAR-T)疗法中T细胞激活与分化的方法。
Methods Mol Biol. 2020;2086:203-211. doi: 10.1007/978-1-0716-0146-4_15.
4
Strategies to Address Chimeric Antigen Receptor Tonic Signaling.应对嵌合抗原受体共刺激信号的策略。
Mol Cancer Ther. 2018 Sep;17(9):1795-1815. doi: 10.1158/1535-7163.MCT-17-1097.
5
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.可逆转的转基因表达减少同室操戈并允许 4-1BB 共刺激 CAR T 细胞靶向 T 细胞恶性肿瘤。
Cancer Immunol Res. 2018 Jan;6(1):47-58. doi: 10.1158/2326-6066.CIR-17-0126. Epub 2017 Oct 27.
6
Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.工程化 γδT 细胞限制嵌合抗原受体相关的 tonic 信号。
Sci Signal. 2019 Sep 10;12(598):eaax1872. doi: 10.1126/scisignal.aax1872.
7
Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.阻断 T 细胞中 CD38 驱动的自相残杀可增强 CD38 特异性嵌合抗原受体 T 细胞的抗肿瘤活性。
J Genet Genomics. 2019 Aug 20;46(8):367-377. doi: 10.1016/j.jgg.2019.06.007. Epub 2019 Aug 13.
8
Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness.嵌合抗原受体的电荷密度调节优化了持续信号和 CAR-T 细胞的适应性。
Cell Res. 2023 May;33(5):341-354. doi: 10.1038/s41422-023-00789-0. Epub 2023 Mar 8.
9
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.框架区修饰消除嵌合抗原受体 T 细胞持续激活信号
Cancer Immunol Res. 2021 Apr;9(4):441-453. doi: 10.1158/2326-6066.CIR-20-0451. Epub 2021 Feb 5.
10
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Breast Cancer Metastasis to the Brain.嵌合抗原受体修饰 T 细胞的区域性递送可有效靶向 HER2 阳性乳腺癌脑转移。
Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23.

引用本文的文献

1
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.下一代免疫疗法设计与工具的见解:分子机制与治疗前景。
J Hematol Oncol. 2025 Jun 7;18(1):62. doi: 10.1186/s13045-025-01701-6.
2
MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence.MARC是一种新型的模块化嵌合抗原受体,它通过防止早期T细胞耗竭和增强持久性来改善基于T细胞的癌症免疫疗法。
J Immunother Cancer. 2025 Apr 20;13(4):e011829. doi: 10.1136/jitc-2025-011829.
3
Sodium citrate pretreatment enhances CAR-T cell persistence and anti-tumor efficacy through inhibition of calcium signaling.
柠檬酸钠预处理通过抑制钙信号增强CAR-T细胞持久性和抗肿瘤疗效。
Front Immunol. 2025 Mar 17;16:1540754. doi: 10.3389/fimmu.2025.1540754. eCollection 2025.
4
Lymph-Node Inspired Hydrogels Enhance CAR Expression and Proliferation of CAR T Cells.受淋巴结启发的水凝胶增强嵌合抗原受体(CAR)的表达及CAR T细胞的增殖
ACS Appl Mater Interfaces. 2025 Mar 19;17(11):16548-16560. doi: 10.1021/acsami.4c19942. Epub 2025 Mar 5.
5
From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy.从体外到体内嵌合抗原T细胞制造:基于CAR-T细胞疗法的新视野
J Transl Med. 2025 Jan 4;23(1):10. doi: 10.1186/s12967-024-06052-3.
6
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen.三种靶向CD79b的新型嵌合抗原受体用于治疗非霍奇金淋巴瘤的临床前开发及靶抗原丢失的特征分析
J Immunother Cancer. 2024 Dec 18;12(12):e009485. doi: 10.1136/jitc-2024-009485.
7
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.嵌合抗原受体自然杀伤(CAR-NK)细胞在癌症治疗中的开发与应用:现状、挑战及新兴治疗进展
Exp Hematol Oncol. 2024 Dec 4;13(1):118. doi: 10.1186/s40164-024-00583-7.
8
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies.T细胞特征对血液系统恶性肿瘤中CAR-T细胞疗法的影响。
Blood Cancer J. 2024 Dec 3;14(1):213. doi: 10.1038/s41408-024-01193-6.
9
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia.蛋白酶体抑制增强了嵌合抗原受体 (CAR) 表达 NK 细胞对急性髓系白血病的抗白血病疗效。
J Hematol Oncol. 2024 Sep 16;17(1):85. doi: 10.1186/s13045-024-01604-y.
10
Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties.嵌合抗原受体 T 细胞携带疱疹病毒进入介质共刺激信号域,表现出抗衰竭特性。
Int J Mol Sci. 2024 Aug 8;25(16):8662. doi: 10.3390/ijms25168662.